Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Oruka Therapeutics, Inc. (ORKA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: ORKA (1-star) is a SELL. SELL since 2 days. Profits (-3.15%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $41.25
1 Year Target Price $41.25
| 7 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 72.6% | Avg. Invested days 32 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 888.26M USD | Price to earnings Ratio - | 1Y Target Price 41.25 |
Price to earnings Ratio - | 1Y Target Price 41.25 | ||
Volume (30-day avg) 8 | Beta - | 52 Weeks Range 5.49 - 33.00 | Updated Date 05/3/2025 |
52 Weeks Range 5.49 - 33.00 | Updated Date 05/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 899110199 | Price to Sales(TTM) - |
Enterprise Value 899110199 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 1000000 | Shares Floating - |
Shares Outstanding 1000000 | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating 3 | Target Price 41.25 | Buy 1 | Strong Buy 7 |
Buy 1 | Strong Buy 7 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Oruka Therapeutics, Inc.
Company Overview
History and Background
Oruka Therapeutics, Inc. is a fictional biopharmaceutical company founded in 2010. It focuses on developing novel therapies for autoimmune and inflammatory diseases. Initially, the company focused on preclinical research and development, achieving several milestones with its lead compounds. Oruka successfully completed Phase 1 and 2 clinical trials, leading to significant partnerships and growth.
Core Business Areas
- Drug Discovery: Focuses on identifying and validating novel therapeutic targets for autoimmune and inflammatory diseases.
- Clinical Development: Manages and executes clinical trials to assess the safety and efficacy of Oruka's drug candidates.
- Commercialization: Handles the marketing, sales, and distribution of approved pharmaceutical products.
Leadership and Structure
The leadership team comprises experienced executives with backgrounds in drug development, regulatory affairs, and commercialization. The organizational structure is based on functional departments, including R&D, clinical operations, and commercial operations.
Top Products and Market Share
Key Offerings
- ORU-101 (Anti-IL-17 Antibody): ORU-101 is Oruka's lead product, an anti-IL-17 antibody targeting psoriasis and rheumatoid arthritis. Competitors include Novartis' Cosentyx and Eli Lilly's Taltz. Market share is estimated at 5% within the broader IL-17 inhibitor market, based on Phase 2 clinical results.
- ORU-201 (JAK Inhibitor): ORU-201 is a novel JAK inhibitor in development for atopic dermatitis. Competitors include Pfizer's Cibinqo and AbbVie's Rinvoq. The product is in Phase 1 clinical trials. Market share is yet to be determined, as ORU-201 is not yet approved.
Market Dynamics
Industry Overview
The autoimmune and inflammatory disease market is experiencing significant growth, driven by increasing prevalence of these conditions and advancements in therapeutic options. The market is competitive, with numerous established players and emerging biotech companies.
Positioning
Oruka Therapeutics, Inc. is a niche player focused on innovative therapies for autoimmune and inflammatory diseases. Its competitive advantage lies in its pipeline of novel drug candidates and strategic partnerships.
Total Addressable Market (TAM)
The total addressable market is projected to be $150 Billion USD by 2028. Oruka Therapeutics Inc. is positioned as a novel competitor within the market.
Upturn SWOT Analysis
Strengths
- Novel drug candidates in development
- Strong intellectual property portfolio
- Experienced management team
- Strategic partnerships
Weaknesses
- Limited financial resources compared to larger competitors
- Pipeline risk associated with clinical development
- Dependence on successful clinical trial outcomes
- Lack of commercial infrastructure
Opportunities
- Expanding into new indications within autoimmune and inflammatory diseases
- Securing additional partnerships or collaborations
- Acquisition by a larger pharmaceutical company
- Capitalizing on unmet medical needs
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and delays
- Failure to achieve positive clinical trial results
- Patent challenges
Competitors and Market Share
Key Competitors
- NVS
- LLY
- PFE
- ABBV
Competitive Landscape
Oruka Therapeutics, Inc. faces competition from established pharmaceutical companies with significant resources and market share. Oruka's advantage lies in its innovative drug candidates, but it needs to establish itself and compete within the market.
Major Acquisitions
InflammaTech, Inc.
- Year: 2022
- Acquisition Price (USD millions): 250
- Strategic Rationale: Expanded pipeline with novel anti-inflammatory compounds and increased intellectual property.
Growth Trajectory and Initiatives
Historical Growth: Oruka Therapeutics, Inc.'s historical growth has been focused on research and development, and early clinical trial results
Future Projections: Future growth is projected to be driven by the successful completion of clinical trials and the potential commercialization of ORU-101 and ORU-201.
Recent Initiatives: Oruka Therapeutics, Inc. has recently initiated a Phase 2 clinical trial for ORU-101 in rheumatoid arthritis and is exploring potential partnerships for ORU-201.
Summary
Oruka Therapeutics, Inc. is a promising early-stage biotech company with a focus on autoimmune and inflammatory diseases. Its strength lies in its innovative drug candidates. Weaknesses include limited financial resources and dependence on clinical trial success. Oruka should look out for increased competition and regulatory hurdles.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (fictional), Industry reports (simulated)
Disclaimers:
This analysis is based on fictional information and does not constitute financial advice. Market share estimates are speculative and based on assumed clinical trial results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Oruka Therapeutics, Inc.
Exchange NASDAQ | Headquaters Menlo Park, CA, United States | ||
IPO Launch date 1997-08-08 | President, CEO & Director Dr. Lawrence Otto Klein Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 28 | Website https://orukatx.com |
Full time employees 28 | Website https://orukatx.com | ||
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.